Dates: 01 January 1970, 1:00 - 1:00 am
The Medicines Patent Pool is thrilled to have taken part in the 2nd World Local Production Forum Enhancing access to medicines and other health technologies in the Hague from 6 to 8 November 2023.
The forum is a WHO initiative that provides the global health community with a regular platform to shape strategies, galvanize collective action, and foster partnerships on sustainable local production to improve timely and equitable access to quality assured health products.
MPP participated in 3 sessions:
MONDAY 6 NOVEMBER
Leap-frogging local production in LMICs with needs-based innovation and talent cultivation
Marie-Paule Kieny, Chair, Governance Board, Medicines Patent Pool talked on the mRNA Technology Transfer Programme.
Chair:
Panel Discussion Speakers:
Theme 3: Tackling the bottlenecks of regional production
Panel 2 discussion: What are the key implementation challenges for regional production
Charles Gore, Executive Director, was part of the panel discussion.
Speakers:
WEDNESDAY 8 NOVEMBER
Geo-diversifying manufacturing capacity through licensing and technology transfer
Esteban Burrone, Head of Policy, Strategy and Market Access spoke on MPP’s work in voluntary licensing and technology transfer.
VISIT OUR BOOTH #5 IN THE MARKETPLACE!
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.